Brentuximab vedotin贝伦妥单抗-维多汀
【商品名】 Adcetris
【曾用名】 SGN-35, c AC10-Val-Cit-MMAE, c AC10-vc MMAE
【化学名】 Im munoglobulin G1, anti-(human CD30 (antigen) ) (human-mouse monoclonal c AC10gam ma1-chain) , disulfide with human-mouse monoclonal c AC10kappa-chain,dimer,complex with N-[ [ [4-[ [ N-[6-(2,5-dihydro-2,5-dioxo-1 H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(ami-nocarbonyl)-L-ornithyl] amino]phenyl] methoxy] carbonyl]-N-methyl-L-valyl-N-[ (1 S,2 R)-4-[ (2 S)-2-[ (1 R,2 R)-3-[ [ (1 R,2 S)-2-hydroxy-1-methyl-2-phenylethyl] amino]-1-me-thoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[ (1 S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide; Im munoglobulin G1, anti-(human tumor necrosis factor receptor superfamily member8(lymphocyte activation antigen CD30 or KI-1 antigen) ;
chimeric (mouse variable domain/human constant do- main) monoclonal c AC10 des-Lysomega(CH3107- K)-gam ma1 heavy chain(220-218 ')-disulfide with chimeric(mouse variable domain/human con-stant domain) monoclonal c AC10 ê light chain,dimer (226-226″:229-229″)-bisdisulfide complex with N-[ [ [4-[ [ N-[6-(2,5-dihydro-2,5-dioxo-1 H-pyrrol-1-yl)-1-oxohexyl]-L valyl-N5-(aminocarbonyl)-L-ornith-yl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[ (1 S,2 R)-4-[ (2 S)-2-[ (1 R,2 R)-3-[ [ (1 R,2 S)-2-hydroxy-1-methyl-2-phenyleth-yl] amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2- me-thoxy-1-[ (1 S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide; Monoclonal antibody-drug conjugate consisting of thechimeric anti-CD30 antibody c AC10 (SGN-30) linked through the Val-Cit linker to8 molecules of the monomethylauristatin E (MMAE)
【CAS登记号】914088-09-8
【上市时间】2011年8月
【上市国家】 美国
【适应证】 治疗CD30高表达的复发性或难治性霍奇金淋巴瘤(自体干细胞移植或既有药物联合治疗失败者)和经至少1种多药化疗方案失败的系统性间变性大淋巴细胞瘤(s ALCL)。
【作用机制】 本品是由抗CD30单抗c AC10、细胞毒类抗癌药物Monomethylauristatin E(MMAE)、可被蛋白酶裂解的化学连接臂三部分组成的抗体-药物耦联物(antibody- drugconjugate, ADC) , ADC通过其抗体部分与肿瘤细胞表面的CD30抗原特异性结合,将具有抗微管药物MMAE运载到肿瘤细胞, ADC迅速内化进入靶细胞,肽连接臂选择性裂解,MMAE释放入细胞通过阻断细胞微管蛋白的聚合而抑制染色体的有丝分裂,随后引起细胞周期停止和细胞凋亡以达到治疗肿瘤的目的。
本小章还未完~.~,请点击下一页继续阅读后面精彩内容!